info@seagull-health.com
SeagullHealth
语言:
search
new
Indications for Methoxsalen (Vitiligo Vulgaris Therapeutic Agent)
504
Article source: Seagull Pharmacy
Oct 20, 2025

Methoxsalen (a therapeutic agent for vulgaris vitiligo) is a photosensitive psoralen derivative, mainly used in PUVA (psoralen + UVA) photochemotherapy for vitiligo and psoriasis.

Indications for Methoxsalen (Vitiligo Vulgaris Therapeutic Agent)

Core Therapeutic Areas

Vitiligo: By enhancing the sensitivity of epidermal melanocytes to UVA (320-400nm), it stimulates the proliferation and migration of residual melanocytes and promotes repigmentation in depigmented areas. It must be used in combination with UVA irradiation and is suitable for patients with stable non-segmental vitiligo.

Psoriasis (main indication in the package insert): Used to control severe, refractory plaque psoriasis that is unresponsive to other treatments. PUVA combination therapy should be implemented only after confirmation by biopsy.

Key Restrictions

Contraindications: Include photosensitive diseases (e.g., lupus erythematosus, porphyria), history of melanoma or squamous cell carcinoma, aphakia (high risk of cataracts), etc.

Special Warnings: Long-term treatment may increase the risk of skin cancer (especially squamous cell carcinoma) and premature aging, requiring lifelong follow-up for skin tumors.

Specifications and Properties of Methoxsalen (Vitiligo Vulgaris Therapeutic Agent)

Dosage Form Characteristics

Specifications: 10mg soft capsules per unit, packaged in amber glass bottles (NDC 0187-0650-42), with 50 capsules per bottle.

Properties: As a soft gel formulation containing natural psoralen derivatives, its bioavailability is twice that of hard capsules, and the time to reach peak concentration is shortened to 1.5-2 hours.

Pharmacological Properties

Photosensitive Mechanism: After oral administration, it forms photoadducts with DNA, inhibiting the proliferation of abnormal keratinocytes (for psoriasis) or stimulating melanin production (for vitiligo).

Metabolic Characteristics: 95% of the drug is metabolized by the liver and excreted in urine within 24 hours, with a half-life of approximately 2 hours.

Storage Methods for Methoxsalen (Vitiligo Vulgaris Therapeutic Agent)

Environmental Requirements

Temperature: Store at 25°C (77°F); short-term fluctuations between 15°C and 30°C (59°F and 86°F) are allowed.

Light Protection: The original amber bottle can effectively block ultraviolet rays; avoid direct sunlight exposure.

Safety Precautions

Child Protection: Store out of the reach of children to prevent accidental ingestion and subsequent phototoxic reactions.

After Opening: It is recommended to use up the product within 6 months. Discard the capsules if they become soft or leak.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Recommended Articles
How to Purchase Methoxsalen (Vitiligo Vulgaris Therapeutic Agent)
Methoxsalen (a therapeutic agent for vulgaris vitiligo) is a prescription medication used in photochemotherapy (PUVA) for vitiligo and psoriasis. It improves symptoms when combined with long-wave ultr...
Precautions for Fampyra Extended-Release Tablets (Fampyra) Use
Fampridine Extended-Release Tablets (Fampyra) are a potassium channel blocker used to improve walking ability in adult patients with multiple sclerosis (MS). As a medication requiring strict dose cont...
How to Use Fampridine Extended-Release Tablets (Fampyra)
Fampridine Extended-Release Tablets (Fampyra) are a potassium channel blocker used to improve walking ability in adult patients with multiple sclerosis (MS).How to Use Fampridine Extended-Release Tabl...
Indications for Fampridine Extended-Release Tablets (Fampyra)
Fampridine Extended-Release Tablets (Fampyra) are a potassium channel blocker approved by the U.S. FDA to improve walking ability in patients with multiple sclerosis (MS).Indications for Fampridine Ex...
Precautions for Administration of Therapeutic Agent for Vulgaris Vitiligo (Methoxsalen)
As a photosensitizing drug, the therapeutic agent for vulgaris vitiligo (Methoxsalen) plays a crucial role in the PUVA therapy (photochemotherapy) for vulgaris vitiligo. This drug exerts its therapeut...
What Are the Side Effects of Therapeutic Agent for Vulgaris Vitiligo (Methoxsalen)?
Therapeutic Agent for Vulgaris Vitiligo (Methoxsalen) is a photosensitizer primarily used in PUVA therapy (psoralen combined with long-wave ultraviolet A irradiation) for vitiligo and psoriasis. As a ...
How to Purchase Seladelpar
Seladelpar, a PPAR-δ agonist approved in 2024, is indicated for the treatment of primary biliary cholangitis (PBC) in patients who have an inadequate response to ursodeoxycholic acid (UDCA). The use o...
Indications for Seladelpar
Seladelpar is a novel peroxisome proliferator-activated receptor delta (PPAR-δ) agonist, which was approved in the United States in 2024 for the treatment of primary biliary cholangitis (PBC).Indicati...
Related Articles
Dosage and Administration, Recommended Dose of Elacestrant (Orserdu)
Elacestrant (Orserdu) is a selective estrogen receptor degrader (SERD), which provides an important treatment option for patients with estrogen receptor-positive, HER2-negative advanced or metastatic ...
What Are the Indications for Elacestrant (Orserdu)?
Elacestrant (Orserdu) is a novel endocrine therapy agent that demonstrates significant value in the treatment of advanced breast cancer with specific gene mutations. As an estrogen receptor antagonist...
What Are the Purchase Channels for Elacestrant (Orserdu)?
With the advancement of medical technology, elacestrant (Orserdu), a targeted drug for breast cancer with specific gene mutations, has brought new treatment options for patients. As the first oral sel...
Adverse Reactions of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor indicated for the treatment of patients with advanced non-small cell lung cancer harboring MET gene mutations. By precisely inhibiting the act...
What are the Precautions for Capmatinib (Tabrecta) Administration?
Capmatinib (Tabrecta) is a targeted therapy drug for MET gene mutations, demonstrating significant efficacy in the treatment of advanced malignancies such as non-small cell lung cancer.What are the Pr...
Dosage and Administration, Recommended Dosage of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor, offering a precision treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation...
What Are the Indications for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a targeted therapy medication that plays an important role in the treatment of non-small cell lung cancer associated with specific gene mutations. As a MET kinase inhibitor, i...
What Are the Purchase Channels for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a highly selective MET inhibitor that has demonstrated significant efficacy in patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutat...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved